Begin typing your search above and press return to search.
proflie-avatar
Login
exit_to_app
Can Trump wield his big stick?
access_time 22 Nov 2024 10:39 AM GMT
election commmission
access_time 22 Nov 2024 4:02 AM GMT
Champions Trophy tournament
access_time 21 Nov 2024 5:00 AM GMT
The illness in health care
access_time 20 Nov 2024 5:00 AM GMT
The fire in Manipur should be put out
access_time 21 Nov 2024 9:19 AM GMT
America should also be isolated
access_time 18 Nov 2024 11:57 AM GMT
DEEP READ
Munambam Waqf issue decoded
access_time 16 Nov 2024 5:18 PM GMT
Ukraine
access_time 16 Aug 2023 5:46 AM GMT
Foreign espionage in the UK
access_time 22 Oct 2024 8:38 AM GMT
exit_to_app
Homechevron_rightIndiachevron_rightCovaxin's production...

Covaxin's production capacity 150 mn doses a year: Centre

text_fields
bookmark_border
Covaxins production capacity 150 mn doses a year: Centre
cancel
camera_alt

Representational image only

New Delhi: The estimated manufacturing capacity of the COVID-19 vaccine, Covishield, is 70-100 million doses per month, while the indigenously developed Covaxin has a planned production capacity of 150 million doses per year, the Department of Biotechnology told a parliamentary panel.

The Parliamentary Standing Committee on Science and Technology, Environment, Forests and Climate Change also strongly urged the department to explore deeper into developing a cure for certain rare diseases, for which the country is, by and large, dependent on imports and patients have to shell out exorbitant amount of money for the cost and their excise/import duty.

The panel also desired to know the status of the current vaccine production capacity with respect to the two approved vaccines, and how soon could these vaccines be made available to non-priority population.

"The inactivated vaccine candidate, COVAXIN, developed jointly by Bharat Biotech and the Indian Council of Medical Research (ICMR), has a planned production capacity of 150 million doses per year," the Department of Biotechnology (DBT) told the panel.

"The estimated manufacturing capacity of the non-replicating viral vector vaccine, COVISHIELD, by the Serum Institute of India Pvt Ltd, is about 70-100 million doses per month," it said.

The report was tabled in the Rajya Sabha on Monday.

30 other vaccines against coronavirus are at different stages of trial.

(with inputs from agencies)

Show Full Article
TAGS:CovaxinvaccineCovid vaccineProduction
Next Story